Abstract:Purpose: We comprehensively searched the plasma metabolome to identify biomarkers related to lung cancer risk among former smokers using pre-diagnostic blood samples collected in two prospective cohort studies: the Shanghai Men's Health Study and the Southern Community Cohort Study. Methods: This nested case-control study includes 237 lung cancer cases and 237 controls individually matched on age, sex, race, smoking pack-year, years since quitting smoking, and blood collection time. The plasma metabolites were measured using Metabolon's Global Discovery Panel. Values of metabolites were log-transformed and compared between cases and controls using the two-tailed paired T-test. Associations of metabolites with lung cancer risk at a False Discovery Rate adjusted p-value (P-FDR) of 8 years), and interval from blood draw to diagnosis (≤6 years and >6 years). Results: We found that 45 plasma metabolites were significantly associated with lung cancer risk (p-FDR<0.10), including 11 in amino acids, 3 in nucleotides, 2 in peptides, 1 in carbohydrates, 7 in lipids, 2 in energy, 2 in xenobiotics, 2 in the partially characterized pathway, and 15 unknown metabolites. Nine metabolites remained statistically significant in the backward selection model. Among them, metabolites significantly associated with increased odds of lung cancer were S-carboxyethylcysteine (OR=1.40; 95% CI: 1.06-1.84), alpha-ketoglutarate (OR=1.60; 95% CI: 1.19-2.16), myristoleoylcarnitine (OR=1.67; 95% CI: 1.27-2.21), 2-hydroxyhippurate (salicylurate) (OR=1.58; 95% CI: 1.16-2.15), gamma-glutamylglutamine (OR=1.68; 95%CI: 1.09-2.61), and an unknown metabolite X-23780 (OR=1.29; 95% CI: 1.00-1.67). Conversely, ceramide (OR=0.60; 95% CI; 0.43-0.82), homoarginine (OR=0.66; 95% CI: 0.49-0.89), and an unknown metabolite X-16935 (OR=0.53; 95% CI= 0.37-0.77) were significantly associated with lower odds of lung cancer. The associations did not vary significantly by race, years since quitting, or interval from blood draw to diagnosis. Conclusion: Several plasma metabolites were associated with lung cancer risk among former smokers. These associations were consistent across race, interval from blood draw to diagnosis, and years since quitting smoking, representing promising biomarkers for identification of high-risk former smokers for lung cancer screening. Citation Format: Thuraya Al-Sayegh, Wanqing Wen, Jie Wu, Wei Zheng, Xiao-Ou Shu, Qiuyin Cai. Global metabolomics identified promising biomarkers for lung cancer risk among former smokers [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 2 (Late-Breaking, Clinical Trial, and Invited s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(7_Suppl) nr LB136.

Development and internal validation of nomograms based on plasma metabolites to predict non‐small cell lung cancer risk in smoking and nonsmoking populations

A Nomogram Diagnostic Prediction Model of Pancreatic Metastases of Small Cell Lung Carcinoma Based on Clinical Characteristics, Radiological Features and Biomarkers

[Exploratory Research on Developing Lung Cancer Risk Prediction Model in Female Non-Smokers].

A nomogram from the SEER database for predicting the prognosis of patients with non-small cell lung cancer

A nomogram based on metabolic profiling to discriminate lung cancer among patients with lung nodules

A Nomogram for Predicting the Risk of Lymph Node Metastasis in T1–2 Non-Small-cell Lung Cancer Based on PET/CT and Clinical Characteristics

Construction and Validation of a Lung Cancer Risk Prediction Model for Non-Smokers in China

Serum Metabolomics Study of Nonsmoking Female Patients with Non-Small Cell Lung Cancer Using Gas Chromatography-Mass Spectrometry.

Development of Nomograms for Predicting Lymph Node Metastasis and Distant Metastasis in Newly Diagnosed T1-2 Non-Small Cell Lung Cancer: A Population-Based Analysis

Risk prediction model for lung cancer incorporating metabolic markers: Development and internal validation in a Chinese population

Development and Validation of a Tumor Marker-Based Model for the Prediction of Lung Cancer: an Analysis of a Multicenter Retrospective Study in Shanghai, China

P2.11-10 Discovery of Potential Biomarkers That Discriminate Early Stage NSCLC from Controls by Non-Targeted Metabolomics Profiling

The prognostic value and model construction of inflammatory markers for patients with non-small cell lung cancer

Abstract LB136: Global metabolomics identified promising biomarkers for lung cancer risk among former smokers

Identification of Metabolic Genes for the Prediction of Prognosis and Tumor Microenvironment Infiltration in Early-Stage Non-Small Cell Lung Cancer.

Clinical Validation of Metabolite Markers for Early Lung Cancer Detection

Construction and validation of a nomogram for non small cell lung cancer patients with liver metastases based on a population analysis

Development and validation of a nomogram model for lung cancer based on radiomics artificial intelligence score and clinical blood test data

A risk model for prediction of lung cancer.

Development and validation of a prognostic nomogram for early stage non-small cell lung cancer: a study based on the SEER database and a Chinese cohort

Metabolite Profiles of the Serum of Patients with Non–Small Cell Carcinoma